Cardiovascular risk estimates and risk factors in renal transplant recipients

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• High cardiovascular morbidity and mortality are significant concerns in renal transplant recipients.
• Both traditional and non-traditional cardiovascular risk factors contribute to this elevated risk.
• Immunosuppressive drugs, including calcineurin inhibitors, can negatively impact cardiovascular risk factors.

Purpose of the Study:

• To compare the effects of tacrolimus and cyclosporine on cardiovascular risk factors in renal transplant patients.
• To assess the differential impact of these immunosuppressants on blood pressure, lipid profiles, and glucose levels.
• To evaluate the predicted 10-year coronary artery disease risk associated with each treatment.

Main Methods:

• A randomized trial (European Tacrolimus versus Cyclosporin A Microemulsion Renal Transplantation Study) involving 557 patients.
• Patients were allocated to receive either tacrolimus (n=286) or cyclosporine (n=271).
• Key cardiovascular risk factors, including blood pressure, lipid profile, blood glucose, and the Framingham risk score, were monitored.

Main Results:

• Tacrolimus use was associated with significantly lower serum cholesterol and mean arterial blood pressure compared to cyclosporine.
• Patients on tacrolimus showed a higher average blood glucose level than those on cyclosporine.
• The estimated 10-year coronary artery disease risk was significantly lower in men treated with tacrolimus but not in women.

Conclusions:

• Tacrolimus and cyclosporine microemulsion demonstrate compound-specific effects on cardiovascular risk factors after renal transplantation.
• These differential effects may lead to varying impacts on the predicted rate of coronary artery disease.
• Treatment choice may influence long-term cardiovascular outcomes in renal transplant recipients.